Rgenta Shows Early ACC Response Data for RGT-61159
WOBURN, Massachusetts, May 21, 2026 Rgenta Therapeutics announced positive preliminary results from its ongoing Phase 1a/b clinical trial evaluating...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
WOBURN, Massachusetts, May 21, 2026 Rgenta Therapeutics announced positive preliminary results from its ongoing Phase 1a/b clinical trial evaluating...
